Wong CA, Saraiya M, Hariri S, Eckert L, Howlett RI, Markowitz LE, Brotherton JM, Sinka K, Martinez-Montañez OG, Kjaer SK, Dunne EF. Source: Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, USA. Abstract In this review, we describe plans to monitor the impact of human papillomavirus (HPV) vaccine on […]
AS04-Adjuvanted Human Papillomavirus (HPV) Types 16 and 18 Vaccine (Cervarix®): A Review of its Use in the Prevention of Premalignant Cervical Lesions and Cervical Cancer Causally Related to Certain Oncogenic HPV Types
McKeage K, Romanowski B; Drugs 71 (4), 465-8 (Mar 2011) The AS04-adjuvanted human papillomavirus (HPV) 16/18 vaccine (Cervarix®) is a noninfectious recombinant vaccine produced using purified virus-like particles (VLPs) that induce a strong immunogenic response eliciting high levels of anti-L1 VLP antibodies that persist at levels markedly greater than those observed with natural infection. The […]
CASP8 promoter polymorphism is associated with high-risk HPV types and abnormal cytology but not with cervical cancer
Chatterjee K, Williamson AL, Hoffman M, Dandara C. Division of Medical Virology and Institute of Infectious Disease and Molecular Medicine (IIDMM), University of Cape Town, Cape Town, Republic of South Africa. Abstract Only a small fraction of women infected with human papillomavirus (HPV) progress to cervical cancer pointing to additional risk factors including host genetics […]
Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection A Randomized Trial
JAMA. 2007;298:743-753. Main Outcome Measures Presence of HPV DNA was determinedin cervical specimins by a molecular hybridization assay usingchemiluminescence with HPV RNA probes and by polymerase chainreaction using SPF10 primers and a line probe assay detectionsystem before vaccination and by polymerase chain reaction aftervaccination. We compared rates of type-specific viral clearanceusing generalized estimating equations methods at […]
Confirmation Of High Efficacy Of HPV Vaccine Against Precancerous Cervical Lesions And Protective Effect Of Vaccination Programs
Article Date: 07 Jul 2009 – 0:00 PDT The findings of the PATRICIA study are reported in an article Online First and in a future edition of The Lancet. It shows that the HPV-16/18 AS04-adjuvanted vaccine (GlaxoSmithKline) has high efficacy against the precancerous cervical lesions that can eventually lead to cervical cancer. There is confirmation […]
